Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Olmutinib |
| Synonyms | |
| Therapy Description |
Olmutinib (BI1482694, HM61713) is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including those occurring with T790M, and spares wild-type EGFR, potentially resulting in decreased tumor growth (PMID: 25027951, PMID: 25521095, PMID: 30356705, PMID: 32830792, PMID: 32679450). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Olmutinib | HM61713|BI 1482694|BI1482694|BI-1482694 | EGFR Inhibitor 3rd gen 28 | Olmutinib (BI1482694, HM61713) is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including those occurring with T790M, and spares wild-type EGFR, potentially resulting in decreased tumor growth (PMID: 25027951, PMID: 25521095, PMID: 30356705, PMID: 32830792, PMID: 32679450). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02485652 | Phase II | Olmutinib | Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | Terminated | USA | ITA | ESP | DEU | CAN | AUS | 4 |